Research Progress of Laboratory Diagnosis of TB
Keywords:
TB, Mycobacterium Tuberculosis, Laboratory Diagnosis
Abstract
Early, rapid, and accurate identification of Mycobacterium tuberculosis is crucial to the treatment and management of the disease, and laboratory diagnosis is an important means for its diagnosis, treatment, and prevention control. Common methods include pathogenic methods based on bacterial smear and culture, molecular methods based on polymerase chain reaction (PCR), immunological methods such as tuberculin skin test and gamma-interferon (IFN-γ) release test, and the latest emergence of molecular methods, such as Xpert MTB/RIF and CRISPR technology have provided new perspectives for TB diagnosis. This review focuses on the main research advances in laboratory diagnosis of TB.References
[1] Natarajan A, Beena P M, Devnikar A V, et al. A systemic review on tuberculosis[J]. Indian J Tuberc, 2020, 67(3): 295-311.
[2] Visca D, Ong C W M, Tiberi S, et al. Tuberculosis and COVID-19 interaction: A review of biological, clinical and public health effects[J]. Pulmonology, 2021, 27(2): 151-165.
[3] Can Sarınoğlu R, Sili U, Eryuksel E, et al. Tuberculosis and COVID-19: An overlapping situation during pandemic[J]. J Infect Dev Ctries, 2020, 14(7): 721-725.
[4] Acharya B, Acharya A, Gautam S, et al. Advances in diagnosis of Tuberculosis: an update into molecular diagnosis of Mycobacterium tuberculosis[J]. Mol Biol Rep, 2020, 47(5): 4065-4075.
[5] Dzodanu EG, Afrifa J, Acheampong DO, et al. Diagnostic Yield of Fluorescence and Ziehl-Neelsen Staining Techniques in the Diagnosis of Pulmonary Tuberculosis: A Comparative Study in a District Health Facility[J]. Tuberc Res Treat, 2019, 2019: 4091937.
[6] Steingart KR, Henry M, Ng V, et al. Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review[J]. Lancet Infect Dis, 2006, 6(9): 570-81.
[7] Steingart KR, Ng V, Henry M, et al. Sputum processing methods to improve the sensitivity of smear microscopy for tuberculosis: a systematic review[J]. Lancet Infect Dis, 2006, 6(10): 664-74.
[8] Bhalla M, Sidiq Z, Sharma P, et al. Performance of light-emitting diode fluorescence microscope for diagnosis of tuberculosis[J], 2013, 2(3): 174-178.
[9] WHO Guidelines Approved by the Guidelines Review Committee, Fluorescent Light-Emitting Diode (LED) Microscopy for Diagnosis of Tuberculosis: Policy Statement, Geneva: World Health Organization Copyright © 2011, World Health Organization., 2011.
[10] Wallace E, Hendrickson D, Tolli N, et al. Culturing Mycobacteria[J]. Methods Mol Biol, 2021, 2314: 1-58.
[11] Kohli A, Bashir G, Fatima A, et al. Rapid drug-susceptibility testing of Mycobacterium tuberculosis clinical isolates to first-line antitubercular drugs by nitrate reductase assay: A comparison with proportion method[J], 2016, 5(4): 469-474.
[12] Maclean E, Kohli M, Weber S F, et al. Advances in Molecular Diagnosis of Tuberculosis[J]. J Clin Microbiol, 2020, 58(10).
[13] Yadav R, Daroch P, Gupta P, et al. Diagnostic accuracy of TB-LAMP assay in patients with pulmonary tuberculosis...a case-control study in northern India[J]. Pulmonology, 2022, 28(6): 449-453.
[14] Kamra E, Mehta PK. Current updates in diagnosis of male urogenital tuberculosis[J]. Expert Rev Anti Infect Ther, 2021, 19(10): 1175-1190.
[15] Umair M, Siddiqui SA, Farooq MA. Diagnostic Accuracy of Sputum Microscopy in Comparison With GeneXpert in Pulmonary Tuberculosis[J]. Cureus, 2020, 12(11): e11383.
[16] Saeed M, Iram S, Hussain S, et al. GeneXpert: A new tool for the rapid detection of rifampicin resistance in mycobacterium tuberculosis[J]. J Pak Med Assoc, 2017, 67(2): 270-274.
[17] Li Z, Hu J, Liu P, et al. Microarray-based selection of a serum biomarker panel that can discriminate between latent and active pulmonary TB[J]. Scientific Reports, 2021, 11(1): 14516.
[18] Wang S, Wu J, Chen J, et al. Evaluation of Mycobacterium tuberculosis-specific antibody responses for the discrimination of active and latent tuberculosis infection[J]. International Journal of Infectious Diseases, 2018, 70: 1-9.
[19] Kisuya J, Chemtai A, Raballah E, et al. The diagnostic accuracy of Th1 (IFN-γ, TNF-α, and IL-2) and Th2 (IL-4, IL-6 and IL-10) cytokines response in AFB microscopy smear negative PTB- HIV co-infected patients[J]. Scientific Reports, 2019, 9(1): 2966.
[20] Abebe F, Holm-Hansen C, Wiker HG, et al. Progress in serodiagnosis of Mycobacterium tuberculosis infection[J]. Scand J Immunol, 2007, 66(2-3): 176-91.
[2] Visca D, Ong C W M, Tiberi S, et al. Tuberculosis and COVID-19 interaction: A review of biological, clinical and public health effects[J]. Pulmonology, 2021, 27(2): 151-165.
[3] Can Sarınoğlu R, Sili U, Eryuksel E, et al. Tuberculosis and COVID-19: An overlapping situation during pandemic[J]. J Infect Dev Ctries, 2020, 14(7): 721-725.
[4] Acharya B, Acharya A, Gautam S, et al. Advances in diagnosis of Tuberculosis: an update into molecular diagnosis of Mycobacterium tuberculosis[J]. Mol Biol Rep, 2020, 47(5): 4065-4075.
[5] Dzodanu EG, Afrifa J, Acheampong DO, et al. Diagnostic Yield of Fluorescence and Ziehl-Neelsen Staining Techniques in the Diagnosis of Pulmonary Tuberculosis: A Comparative Study in a District Health Facility[J]. Tuberc Res Treat, 2019, 2019: 4091937.
[6] Steingart KR, Henry M, Ng V, et al. Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review[J]. Lancet Infect Dis, 2006, 6(9): 570-81.
[7] Steingart KR, Ng V, Henry M, et al. Sputum processing methods to improve the sensitivity of smear microscopy for tuberculosis: a systematic review[J]. Lancet Infect Dis, 2006, 6(10): 664-74.
[8] Bhalla M, Sidiq Z, Sharma P, et al. Performance of light-emitting diode fluorescence microscope for diagnosis of tuberculosis[J], 2013, 2(3): 174-178.
[9] WHO Guidelines Approved by the Guidelines Review Committee, Fluorescent Light-Emitting Diode (LED) Microscopy for Diagnosis of Tuberculosis: Policy Statement, Geneva: World Health Organization Copyright © 2011, World Health Organization., 2011.
[10] Wallace E, Hendrickson D, Tolli N, et al. Culturing Mycobacteria[J]. Methods Mol Biol, 2021, 2314: 1-58.
[11] Kohli A, Bashir G, Fatima A, et al. Rapid drug-susceptibility testing of Mycobacterium tuberculosis clinical isolates to first-line antitubercular drugs by nitrate reductase assay: A comparison with proportion method[J], 2016, 5(4): 469-474.
[12] Maclean E, Kohli M, Weber S F, et al. Advances in Molecular Diagnosis of Tuberculosis[J]. J Clin Microbiol, 2020, 58(10).
[13] Yadav R, Daroch P, Gupta P, et al. Diagnostic accuracy of TB-LAMP assay in patients with pulmonary tuberculosis...a case-control study in northern India[J]. Pulmonology, 2022, 28(6): 449-453.
[14] Kamra E, Mehta PK. Current updates in diagnosis of male urogenital tuberculosis[J]. Expert Rev Anti Infect Ther, 2021, 19(10): 1175-1190.
[15] Umair M, Siddiqui SA, Farooq MA. Diagnostic Accuracy of Sputum Microscopy in Comparison With GeneXpert in Pulmonary Tuberculosis[J]. Cureus, 2020, 12(11): e11383.
[16] Saeed M, Iram S, Hussain S, et al. GeneXpert: A new tool for the rapid detection of rifampicin resistance in mycobacterium tuberculosis[J]. J Pak Med Assoc, 2017, 67(2): 270-274.
[17] Li Z, Hu J, Liu P, et al. Microarray-based selection of a serum biomarker panel that can discriminate between latent and active pulmonary TB[J]. Scientific Reports, 2021, 11(1): 14516.
[18] Wang S, Wu J, Chen J, et al. Evaluation of Mycobacterium tuberculosis-specific antibody responses for the discrimination of active and latent tuberculosis infection[J]. International Journal of Infectious Diseases, 2018, 70: 1-9.
[19] Kisuya J, Chemtai A, Raballah E, et al. The diagnostic accuracy of Th1 (IFN-γ, TNF-α, and IL-2) and Th2 (IL-4, IL-6 and IL-10) cytokines response in AFB microscopy smear negative PTB- HIV co-infected patients[J]. Scientific Reports, 2019, 9(1): 2966.
[20] Abebe F, Holm-Hansen C, Wiker HG, et al. Progress in serodiagnosis of Mycobacterium tuberculosis infection[J]. Scand J Immunol, 2007, 66(2-3): 176-91.
Published
2023-03-21
Issue
Section
Original Research Article
Copyright (c) 2023 Mimi Zhang
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors submitting to USP journals agree to publish their manuscript under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) where authors agree to allow third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear
Authors retain copyright of their work, with first publication rights (online and print) granted to Universe Scientific Publishing or the owner of the journal in question.
